Resonant Clinical Solutions Names Christophe Berthoux as CEO to Drive Global Expansion
Key Insights
Resonant Clinical Solutions (search), a global provider of clinical trial services, has appointed Dr. Christophe Berthoux (search) as Chief Executive Officer effective immediately.
Berthoux brings over three decades of pharmaceutical services leadership experience, including CEO roles at NAMSA (search), Synexus (search), and CitoxLab (search).
The appointment follows Audax Private Equity (search)'s acquisition of Resonant from Avantor (search) in 2024, marking a strategic milestone in the company's evolution.
Resonant Clinical Solutions (search) has appointed Dr. Christophe Berthoux (search) as its Chief Executive Officer, effective immediately, as the global clinical trial services provider seeks to accelerate growth under new private equity ownership. The appointment represents a strategic milestone following Audax Private Equity (search)'s acquisition of the business from Avantor (search) in 2024.
Seasoned Industry Leader Takes the Helm
Berthoux brings more than three decades of leadership experience in the pharmaceutical services industry, including senior roles across clinical research organizations, preclinical services, and patient recruitment solutions. Most recently, he served as CEO of private equity-backed NAMSA (search), where he meaningfully scaled the business through a combination of organic and M&A-driven growth.
Prior to NAMSA (search), Berthoux held CEO roles at Synexus (search), a patient recruitment business acquired by PPD, and CitoxLab (search), which was acquired by Charles River Laboratories. Earlier in his career, he spent nearly two decades at Charles River Laboratories in senior leadership roles across Europe and North America, culminating as its Chief Commercial Officer.
"We are thrilled to welcome Christophe to Resonant," said David Wong, Partner at Audax. "We believe his track record of building and scaling global pharmaceutical-services companies through both organic and inorganic growth makes him the ideal leader to drive the next phase of Resonant's evolution as a stand-alone business."
Strategic Vision for Growth
Berthoux expressed enthusiasm about joining the company at this pivotal moment. "I am honored to join Resonant at such an exciting time," he said. "The company, and its existing well-respected brands, together have a long track record of differentiated customer service and deep expertise in clinical trial kitting, equipment and ancillary services, and biorepository management."
The new CEO emphasized his commitment to building on the company's foundation while expanding its value proposition across domestic and global customer bases. Wong noted that Audax looks forward to partnering with Berthoux to expand Resonant's capabilities, customer base, and geographic reach while maintaining high-quality service standards.
Company Transformation Under New Ownership
Since joining the Audax portfolio, Resonant has initiated meaningful investments in infrastructure, operational excellence, and customer service, seeking to accelerate growth and scale its offering across clinical-trial services markets globally. The appointment of Berthoux marks an important milestone in this evolution.
With over 850 employees across the US, UK, and Europe, Resonant Clinical Solutions (search) provides clinical trial and laboratory supply chain services to pharmaceutical and biotechnology companies, contract research organizations (CROs), and diagnostic laboratories. The company positions itself as an agile partner to life science enterprises, offering personalized solutions that advance clinical and commercial operations from development to delivery.
Private Equity Backing Fuels Expansion
Audax Private Equity (search), based in Boston and San Francisco, manages approximately $19 billion of assets under management as of March 2025. The firm has invested in 175 platforms and 1,350 add-on acquisitions since its founding in 1999, employing a disciplined Buy & Build approach across six core industry verticals to help portfolio companies execute organic and inorganic growth initiatives.